BOSTON – November 28, 2016 -- OncoPep, Inc. announced that a Phase 1b clinical trial is underway to evaluate PVX-410, a multi-peptide therapeutic cancer vaccine, as an adjuvant treatment in patients who have completed all planned therapy...
BOSTON – November 28, 2016 -- OncoPep, Inc. today announced the initiation of a Phase 1b clinical trial evaluating PVX-410, a multi-peptide therapeutic cancer vaccine, in patients with moderate or high-risk for progression smoldering...
BOSTON – August 28, 2014 -- OncoPep, Inc., today announced the closing of $6.9 million in Series B financing from new and existing investors. The financing included participation from angel groups, family foundations and individuals, as...
BOSTON -- January 29, 2013 -- OncoPep, Inc. today announced that the Company has initiated a Phase 1/2a clinical trial evaluating PVX-410, a multi-peptide therapeutic cancer vaccine, in patients with smoldering multiple myeloma, an...